Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

We proposed to use 4 cycles of AC q 2 weeks, as used in the dose dense adjuvant study with GM-CSF support on days 3-9 of the cycle. After the completion of AC we plan to administer paclitaxel and carboplatin weekly for a total of 12 doses with one week rest after every 3 weeks of treatment over 12 weeks. Patients who are her-2 over-expressors by FISH (fluorescence in situ hybridization) will also receive Trastuzumab with weekly carboplatin and paclitaxel as the combination TC±H has been found to be synergistic in advanced breast cancer with improved clinical outcome.

Key facts

Study ID
NCT00256243
Run by
Rita Sanghvi, Mehta
People needed
48
Starts
2004-04-01
Expected to finish
2012-07-01
Last updated by the study team
2018-03-02

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.